Advertisement

Index by author

September 01, 1996; Volume 278,Issue 3

A

  1. Aarbakke, J

    1. Apoptosis and transmethylation metabolites in HL-60 cells.
      P C Endresen, T Loennechen, H Kildalsen and J Aarbakke
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1318-1324;

  2. Abel, P W

    1. Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats.
      C S Bockman, I Gonzalez-Cabrera and P W Abel
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1235-1243;

  3. Abood, M E

    1. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
      V M Showalter, D R Compton, B R Martin and M E Abood
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 989-999;

  4. Aceto, M D

    1. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
      M D Aceto, S M Scates, J A Lowe and B R Martin
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1290-1295;

  5. Aghajanian, G K

    1. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
      G J Marek and G K Aghajanian
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1373-1382;

  6. Akil, H

    1. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
      P J Emmerson, M J Clark, A Mansour, H Akil, J H Woods and F Medzihradsky
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1121-1127;

  7. Albuquerque, E X

    1. Paraoxon: cholinesterase-independent stimulation of transmitter release and selective block of ligand-gated ion channels in cultured hippocampal neurons.
      E S Rocha, K L Swanson, Y Aracava, J E Goolsby, A Maelicke and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1175-1187;
    2. Diversity of nicotinic acetylcholine receptors in rat brain. V. alpha-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release.
      M Alkondon, E S Rocha, A Maelicke and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1460-1471;
    3. Alpha-conotoxin-ImI: a competitive antagonist at alpha-bungarotoxin-sensitive neuronal nicotinic receptors in hippocampal neurons.
      E F Pereira, M Alkondon, J M McIntosh and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1472-1483;

  8. Aliño, S F

    1. Specific serological response by active immunization with GD3-bearing liposomes.
      O Massó, S F Aliño, M Lejarreta, F Blasco and J Piulats
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1114-1120;

  9. Alkondon, M

    1. Diversity of nicotinic acetylcholine receptors in rat brain. V. alpha-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release.
      M Alkondon, E S Rocha, A Maelicke and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1460-1471;
    2. Alpha-conotoxin-ImI: a competitive antagonist at alpha-bungarotoxin-sensitive neuronal nicotinic receptors in hippocampal neurons.
      E F Pereira, M Alkondon, J M McIntosh and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1472-1483;

  10. Aracava, Y

    1. Paraoxon: cholinesterase-independent stimulation of transmitter release and selective block of ligand-gated ion channels in cultured hippocampal neurons.
      E S Rocha, K L Swanson, Y Aracava, J E Goolsby, A Maelicke and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1175-1187;

  11. Araki, H

    1. Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
      T Takahashi, K Takahashi, S Kishi-Tanikawa, K Tsuchida, H Araki and S Higuchi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1028-1033;

  12. Archer, S

    1. Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys.
      M B Gatch, S S Negus, N K Mello, S Archer and J M Bidlack
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1282-1289;

  13. Artigas, F

    1. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies.
      N Bel and F Artigas
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1064-1072;

  14. Avram, M J

    1. Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly.
      T C Krejcie, T K Henthorn, C U Niemann, C Klein, D K Gupta, W B Gentry, C A Shanks and M J Avram
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1050-1057;

B

  1. Ballenger, C A

    1. Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat.
      M J Owens, C A Ballenger, D L Knight and C B Nemeroff
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1040-1049;

  2. Barbarito, E J

    1. Tolerance to the anxiolytic effects of the triazolobenzodiazepines triazolam and alprazolam, as measured by the ingestion of a hypertonic sodium chloride solution in rats.
      E J Barbarito, C E Lau and J L Falk
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1201-1208;

  3. Bazemore, S A

    1. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.
      T L Wallace, S A Bazemore, D J Kornbrust and P A Cossum
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1306-1312;
    2. Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys.
      T L Wallace, S A Bazemore, D J Kornbrust and P A Cossum
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1313-1317;

  4. Bean, J S

    1. Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran.
      T R Wiernicki, J S Bean, C Dell, A Williams, D Wood, R F Kauffman and J P Singh
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1452-1459;

  5. Beijer, B

    1. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
      J P Desjardins, B S Sproat, B Beijer, M Blaschke, M Dunkel, W Gerdes, J Ludwig, V Reither, T Rupp and P L Iversen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1419-1427;

  6. Bel, N

    1. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies.
      N Bel and F Artigas
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1064-1072;

  7. Bellward, G D

    1. Peripubertal androgen imprinting of rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase: pretranslational regulation and impact on microsomal drug activation.
      T K Chang and G D Bellward
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1383-1391;

  8. Bend, J R

    1. Microsomal cytochrome P450 peroxygenase metabolism of arachidonic acid in guinea pig liver.
      G P McCallum, A C Weedon, P Krug and J R Bend
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1188-1194;

  9. Benet, L Z

    1. In vivo depletion of free thiols does not account for nitroglycerin-induced tolerance: a thiol-nitrate interaction hypothesis as an alternative explanation for nitroglycerin activity and tolerance.
      A I Haj-Yehia and L Z Benet
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1296-1305;

  10. Beyer, M E

    1. Significance of endothelinB receptors for myocardial contractility and myocardial energy metabolism.
      M E Beyer, G Slesak and H M Hoffmeister
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1228-1234;

  11. Bidlack, J M

    1. Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys.
      M B Gatch, S S Negus, N K Mello, S Archer and J M Bidlack
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1282-1289;

  12. Biscardi, R

    1. Effects of benzodiazepine agonist exposure on corticotropin-releasing factor content and hormonal stress responses: divergent responses in male and ovariectomized female rats.
      M A Wilson, R Biscardi, M D Smith and S P Wilson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1073-1082;

  13. Blaschke, M

    1. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
      J P Desjardins, B S Sproat, B Beijer, M Blaschke, M Dunkel, W Gerdes, J Ludwig, V Reither, T Rupp and P L Iversen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1419-1427;

  14. Blasco, F

    1. Specific serological response by active immunization with GD3-bearing liposomes.
      O Massó, S F Aliño, M Lejarreta, F Blasco and J Piulats
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1114-1120;

  15. Bless, E P

    1. Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats.
      A E Kelley, E P Bless and C J Swanson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1499-1507;

  16. Bockman, C S

    1. Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats.
      C S Bockman, I Gonzalez-Cabrera and P W Abel
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1235-1243;

  17. Bost, J E

    1. Effects of cocaine on anterior pituitary and gonadal hormones.
      C M Heesch, B H Negus, J E Bost, J H Keffer, R W Snyder and E J Eichhorn
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1195-1200;

  18. Broudy, E P

    1. Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model.
      J A Schriefer, E P Broudy and A H Hassen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1034-1039;

  19. Buben, J A

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

  20. Buckpitt, A

    1. Cellular and metabolic basis of Clara cell tolerance to multiple doses of cytochrome P450-activated cytotoxicants. I: Bronchiolar epithelial reorganization and expression of cytochrome P450 monooxygenases in mice exposed to multiple doses of naphthalene.
      J Lakritz, A Chang, A Weir, S Nishio, D Hyde, R Philpot, A Buckpitt and C Plopper
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1408-1418;

  21. Bylund, D B

    1. Buffers differentially alter the binding of [3H]rauwolscine and [3H]RX821002 to the alpha-2 adrenergic receptor subtypes.
      J D Deupree, K A Hinton, D R Cerutis and D B Bylund
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1215-1227;

C

  1. Calderon, S

    1. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80.
      E Malatynska, Y Wang, R J Knapp, S Waite, S Calderon, K Rice, V J Hruby, H I Yamamura and W R Roeske
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1083-1089;

  2. Cameron, N E

    1. Effects of a nonpeptide endothelin-1 ETA antagonist on neurovascular function in diabetic rats: interaction with the renin-angiotensin system.
      N E Cameron and M A Cotter
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1262-1268;

  3. Canet, E

    1. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
      L Foissier, M Lonchampt, F Cogé and E Canet
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1484-1490;

  4. Caraco, Y

    1. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
      Y Caraco, J Sheller and A J Wood
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1165-1174;

  5. Cerutis, D R

    1. Buffers differentially alter the binding of [3H]rauwolscine and [3H]RX821002 to the alpha-2 adrenergic receptor subtypes.
      J D Deupree, K A Hinton, D R Cerutis and D B Bylund
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1215-1227;

  6. Cervera, L S

    1. Expression and modulation of 5-hydroxytryptamine1A receptors in P11 cells.
      J G Hensler, L S Cervera, H A Miller and J Corbitt
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1138-1145;

  7. Cervoni, P

    1. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs.
      Y T Shen, P Cervoni, T Claus and S F Vatner
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1435-1443;

  8. Chang, A

    1. Cellular and metabolic basis of Clara cell tolerance to multiple doses of cytochrome P450-activated cytotoxicants. I: Bronchiolar epithelial reorganization and expression of cytochrome P450 monooxygenases in mice exposed to multiple doses of naphthalene.
      J Lakritz, A Chang, A Weir, S Nishio, D Hyde, R Philpot, A Buckpitt and C Plopper
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1408-1418;

  9. Chang, T K

    1. Peripubertal androgen imprinting of rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase: pretranslational regulation and impact on microsomal drug activation.
      T K Chang and G D Bellward
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1383-1391;

  10. Cheng, J B

    1. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4.
      C R Turner, V L Cohan, J B Cheng, H J Showell, C J Pazoles and J W Watson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1349-1355;
    2. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
      V L Cohan, H J Showell, D A Fisher, C J Pazoles, J W Watson, C R Turner and J B Cheng
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1356-1361;

  11. Clark, M J

    1. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
      P J Emmerson, M J Clark, A Mansour, H Akil, J H Woods and F Medzihradsky
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1121-1127;

  12. Claus, T

    1. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs.
      Y T Shen, P Cervoni, T Claus and S F Vatner
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1435-1443;

  13. Codd, E E

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

  14. Cogé, F

    1. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
      L Foissier, M Lonchampt, F Cogé and E Canet
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1484-1490;

  15. Cohan, V L

    1. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4.
      C R Turner, V L Cohan, J B Cheng, H J Showell, C J Pazoles and J W Watson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1349-1355;
    2. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
      V L Cohan, H J Showell, D A Fisher, C J Pazoles, J W Watson, C R Turner and J B Cheng
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1356-1361;

  16. Compton, D R

    1. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
      V M Showalter, D R Compton, B R Martin and M E Abood
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 989-999;

  17. Connelly, C D

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

  18. Corbitt, J

    1. Expression and modulation of 5-hydroxytryptamine1A receptors in P11 cells.
      J G Hensler, L S Cervera, H A Miller and J Corbitt
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1138-1145;

  19. Cossum, P A

    1. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.
      T L Wallace, S A Bazemore, D J Kornbrust and P A Cossum
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1306-1312;
    2. Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys.
      T L Wallace, S A Bazemore, D J Kornbrust and P A Cossum
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1313-1317;

  20. Cotter, M A

    1. Effects of a nonpeptide endothelin-1 ETA antagonist on neurovascular function in diabetic rats: interaction with the renin-angiotensin system.
      N E Cameron and M A Cotter
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1262-1268;

  21. Czernik, A J

    1. Increased in vivo phosphorylation state of neuromodulin and synapsin I in striatum from rats treated with repeated amphetamine.
      S Iwata, G H Hewlett, S T Ferrell, A J Czernik, K F Meiri and M E Gnegy
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1428-1434;

D

  1. Davis, C

    1. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene.
      N R Kitteringham, C Davis, N Howard, M Pirmohamed and B K Park
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1018-1027;

  2. Dell, C

    1. Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran.
      T R Wiernicki, J S Bean, C Dell, A Williams, D Wood, R F Kauffman and J P Singh
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1452-1459;

  3. Desjardins, J P

    1. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
      J P Desjardins, B S Sproat, B Beijer, M Blaschke, M Dunkel, W Gerdes, J Ludwig, V Reither, T Rupp and P L Iversen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1419-1427;

  4. Deupree, J D

    1. Buffers differentially alter the binding of [3H]rauwolscine and [3H]RX821002 to the alpha-2 adrenergic receptor subtypes.
      J D Deupree, K A Hinton, D R Cerutis and D B Bylund
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1215-1227;

  5. Dionisotti, S

    1. Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261.
      S Dionisotti, S Ferrara, C Molta, C Zocchi and E Ongini
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1209-1214;

  6. Dunkel, M

    1. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
      J P Desjardins, B S Sproat, B Beijer, M Blaschke, M Dunkel, W Gerdes, J Ludwig, V Reither, T Rupp and P L Iversen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1419-1427;

E

  1. Eichhorn, E J

    1. Effects of cocaine on anterior pituitary and gonadal hormones.
      C M Heesch, B H Negus, J E Bost, J H Keffer, R W Snyder and E J Eichhorn
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1195-1200;

  2. Emmerson, P J

    1. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
      P J Emmerson, M J Clark, A Mansour, H Akil, J H Woods and F Medzihradsky
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1121-1127;

  3. Endresen, P C

    1. Apoptosis and transmethylation metabolites in HL-60 cells.
      P C Endresen, T Loennechen, H Kildalsen and J Aarbakke
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1318-1324;

F

  1. Falk, J L

    1. Tolerance to the anxiolytic effects of the triazolobenzodiazepines triazolam and alprazolam, as measured by the ingestion of a hypertonic sodium chloride solution in rats.
      E J Barbarito, C E Lau and J L Falk
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1201-1208;

  2. Ferrara, S

    1. Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261.
      S Dionisotti, S Ferrara, C Molta, C Zocchi and E Ongini
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1209-1214;

  3. Ferrell, S T

    1. Increased in vivo phosphorylation state of neuromodulin and synapsin I in striatum from rats treated with repeated amphetamine.
      S Iwata, G H Hewlett, S T Ferrell, A J Czernik, K F Meiri and M E Gnegy
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1428-1434;

  4. Ferrier, G R

    1. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion.
      G P Thomas, G R Ferrier and S E Howlett
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1090-1097;

  5. Fischman, M W

    1. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
      R W Foltin and M W Fischman
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1153-1164;

  6. Fisher, D A

    1. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
      V L Cohan, H J Showell, D A Fisher, C J Pazoles, J W Watson, C R Turner and J B Cheng
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1356-1361;

  7. Foissier, L

    1. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
      L Foissier, M Lonchampt, F Cogé and E Canet
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1484-1490;

  8. Foltin, R W

    1. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
      R W Foltin and M W Fischman
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1153-1164;

  9. Friden, P M

    1. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor.
      P M Friden, T S Olson, R Obar, L R Walus and S D Putney
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1491-1498;

G

  1. Gamache, D A

    1. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
      N A Sharif, S X Xu, S T Miller, D A Gamache and J M Yanni
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1252-1261;

  2. Gatch, M B

    1. Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys.
      M B Gatch, S S Negus, N K Mello, S Archer and J M Bidlack
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1282-1289;

  3. Gentry, W B

    1. Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly.
      T C Krejcie, T K Henthorn, C U Niemann, C Klein, D K Gupta, W B Gentry, C A Shanks and M J Avram
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1050-1057;

  4. Gerdes, W

    1. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
      J P Desjardins, B S Sproat, B Beijer, M Blaschke, M Dunkel, W Gerdes, J Ludwig, V Reither, T Rupp and P L Iversen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1419-1427;

  5. Gnegy, M E

    1. Increased in vivo phosphorylation state of neuromodulin and synapsin I in striatum from rats treated with repeated amphetamine.
      S Iwata, G H Hewlett, S T Ferrell, A J Czernik, K F Meiri and M E Gnegy
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1428-1434;

  6. Gonzalez-Cabrera, I

    1. Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats.
      C S Bockman, I Gonzalez-Cabrera and P W Abel
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1235-1243;

  7. Goolsby, J E

    1. Paraoxon: cholinesterase-independent stimulation of transmitter release and selective block of ligand-gated ion channels in cultured hippocampal neurons.
      E S Rocha, K L Swanson, Y Aracava, J E Goolsby, A Maelicke and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1175-1187;

  8. Gunther, R

    1. Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity.
      C May, R I James, R Gunther and R S McIvor
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1444-1451;

  9. Gupta, D K

    1. Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly.
      T C Krejcie, T K Henthorn, C U Niemann, C Klein, D K Gupta, W B Gentry, C A Shanks and M J Avram
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1050-1057;

H

  1. Haj-Yehia, A I

    1. In vivo depletion of free thiols does not account for nitroglycerin-induced tolerance: a thiol-nitrate interaction hypothesis as an alternative explanation for nitroglycerin activity and tolerance.
      A I Haj-Yehia and L Z Benet
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1296-1305;

  2. Haslego, M L

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

  3. Hassen, A H

    1. Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model.
      J A Schriefer, E P Broudy and A H Hassen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1034-1039;

  4. Hayaishi, O

    1. Prostaglandin D2 inhibits prostaglandin E2-induced allodynia in conscious mice.
      T Minami, E Okuda-Ashitaka, H Mori, S Ito and O Hayaishi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1146-1152;

  5. Heesch, C M

    1. Effects of cocaine on anterior pituitary and gonadal hormones.
      C M Heesch, B H Negus, J E Bost, J H Keffer, R W Snyder and E J Eichhorn
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1195-1200;

  6. Hensler, J G

    1. Expression and modulation of 5-hydroxytryptamine1A receptors in P11 cells.
      J G Hensler, L S Cervera, H A Miller and J Corbitt
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1138-1145;

  7. Henthorn, T K

    1. Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly.
      T C Krejcie, T K Henthorn, C U Niemann, C Klein, D K Gupta, W B Gentry, C A Shanks and M J Avram
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1050-1057;

  8. Hewlett, G H

    1. Increased in vivo phosphorylation state of neuromodulin and synapsin I in striatum from rats treated with repeated amphetamine.
      S Iwata, G H Hewlett, S T Ferrell, A J Czernik, K F Meiri and M E Gnegy
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1428-1434;

  9. Higuchi, S

    1. Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
      T Takahashi, K Takahashi, S Kishi-Tanikawa, K Tsuchida, H Araki and S Higuchi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1028-1033;

  10. Hinton, K A

    1. Buffers differentially alter the binding of [3H]rauwolscine and [3H]RX821002 to the alpha-2 adrenergic receptor subtypes.
      J D Deupree, K A Hinton, D R Cerutis and D B Bylund
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1215-1227;

  11. Hirasaki, A

    1. Use of nitric oxide-nucleophile adducts as biological sources of nitric oxide: effects on airway smooth muscle.
      A Hirasaki, K A Jones, W J Perkins and D O Warner
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1269-1275;

  12. Hoffmeister, H M

    1. Significance of endothelinB receptors for myocardial contractility and myocardial energy metabolism.
      M E Beyer, G Slesak and H M Hoffmeister
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1228-1234;

  13. Hosokawa, M

    1. ONO-1078 antagonizes diarrhea-causing changes in ion transport and smooth muscle contraction induced by peptidoleukotrienes in rat and human colon in vitro.
      M Tominaga, H Tsukada, M Hosokawa, H Nakamura, T Taniguchi, S Ueda, M Sakai and M Okuma
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1058-1063;

  14. Howard, N

    1. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene.
      N R Kitteringham, C Davis, N Howard, M Pirmohamed and B K Park
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1018-1027;

  15. Howlett, S E

    1. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion.
      G P Thomas, G R Ferrier and S E Howlett
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1090-1097;

  16. Hruby, V J

    1. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80.
      E Malatynska, Y Wang, R J Knapp, S Waite, S Calderon, K Rice, V J Hruby, H I Yamamura and W R Roeske
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1083-1089;

  17. Hyde, D

    1. Cellular and metabolic basis of Clara cell tolerance to multiple doses of cytochrome P450-activated cytotoxicants. I: Bronchiolar epithelial reorganization and expression of cytochrome P450 monooxygenases in mice exposed to multiple doses of naphthalene.
      J Lakritz, A Chang, A Weir, S Nishio, D Hyde, R Philpot, A Buckpitt and C Plopper
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1408-1418;

I

  1. Ito, S

    1. Prostaglandin D2 inhibits prostaglandin E2-induced allodynia in conscious mice.
      T Minami, E Okuda-Ashitaka, H Mori, S Ito and O Hayaishi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1146-1152;

  2. Iversen, P L

    1. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
      J P Desjardins, B S Sproat, B Beijer, M Blaschke, M Dunkel, W Gerdes, J Ludwig, V Reither, T Rupp and P L Iversen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1419-1427;

  3. Iwasa, S

    1. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15.
      D Nakai, T Seita, T Terasaki, S Iwasa, Y Shoji, Y Mizushima and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1362-1372;

  4. Iwata, S

    1. Increased in vivo phosphorylation state of neuromodulin and synapsin I in striatum from rats treated with repeated amphetamine.
      S Iwata, G H Hewlett, S T Ferrell, A J Czernik, K F Meiri and M E Gnegy
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1428-1434;

J

  1. James, R I

    1. Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity.
      C May, R I James, R Gunther and R S McIvor
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1444-1451;

  2. Jones, K A

    1. Use of nitric oxide-nucleophile adducts as biological sources of nitric oxide: effects on airway smooth muscle.
      A Hirasaki, K A Jones, W J Perkins and D O Warner
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1269-1275;

K

  1. Kamada, H

    1. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
      Y Tsutsumi, T Kihira, S Tsunoda, H Kamada, S Nakagawa, Y Kaneda, T Kanamori and T Mayumi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1006-1011;

  2. Kanamori, T

    1. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
      Y Tsutsumi, T Kihira, S Tsunoda, H Kamada, S Nakagawa, Y Kaneda, T Kanamori and T Mayumi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1006-1011;

  3. Kaneda, Y

    1. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
      Y Tsutsumi, T Kihira, S Tsunoda, H Kamada, S Nakagawa, Y Kaneda, T Kanamori and T Mayumi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1006-1011;

  4. Karim, F

    1. Spinal morphine/clonidine antinociceptive synergism: involvement of G proteins and N-type voltage-dependent calcium channels.
      Z Y Wei, F Karim and S C Roerig
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1392-1407;

  5. Kauffman, R F

    1. Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran.
      T R Wiernicki, J S Bean, C Dell, A Williams, D Wood, R F Kauffman and J P Singh
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1452-1459;

  6. Keffer, J H

    1. Effects of cocaine on anterior pituitary and gonadal hormones.
      C M Heesch, B H Negus, J E Bost, J H Keffer, R W Snyder and E J Eichhorn
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1195-1200;

  7. Kelley, A E

    1. Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats.
      A E Kelley, E P Bless and C J Swanson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1499-1507;

  8. Kihira, T

    1. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
      Y Tsutsumi, T Kihira, S Tsunoda, H Kamada, S Nakagawa, Y Kaneda, T Kanamori and T Mayumi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1006-1011;

  9. Kildalsen, H

    1. Apoptosis and transmethylation metabolites in HL-60 cells.
      P C Endresen, T Loennechen, H Kildalsen and J Aarbakke
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1318-1324;

  10. Kishi-Tanikawa, S

    1. Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
      T Takahashi, K Takahashi, S Kishi-Tanikawa, K Tsuchida, H Araki and S Higuchi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1028-1033;

  11. Kitteringham, N R

    1. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene.
      N R Kitteringham, C Davis, N Howard, M Pirmohamed and B K Park
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1018-1027;

  12. Klein, C

    1. Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly.
      T C Krejcie, T K Henthorn, C U Niemann, C Klein, D K Gupta, W B Gentry, C A Shanks and M J Avram
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1050-1057;

  13. Knapp, R J

    1. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80.
      E Malatynska, Y Wang, R J Knapp, S Waite, S Calderon, K Rice, V J Hruby, H I Yamamura and W R Roeske
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1083-1089;

  14. Knight, D L

    1. Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat.
      M J Owens, C A Ballenger, D L Knight and C B Nemeroff
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1040-1049;

  15. Kornbrust, D J

    1. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.
      T L Wallace, S A Bazemore, D J Kornbrust and P A Cossum
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1306-1312;
    2. Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys.
      T L Wallace, S A Bazemore, D J Kornbrust and P A Cossum
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1313-1317;

  16. Krejcie, T C

    1. Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly.
      T C Krejcie, T K Henthorn, C U Niemann, C Klein, D K Gupta, W B Gentry, C A Shanks and M J Avram
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1050-1057;

  17. Krone, M

    1. Is inhibition of oxygen radical production of neutrophils by sympathomimetics mediated via beta-2 adrenoceptors?
      M Weiss, E M Schneider, J Tarnow, S Mettler, M Krone, A Teschemacher and H Lemoine
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1105-1113;

  18. Krug, P

    1. Microsomal cytochrome P450 peroxygenase metabolism of arachidonic acid in guinea pig liver.
      G P McCallum, A C Weedon, P Krug and J R Bend
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1188-1194;

L

  1. Lakritz, J

    1. Cellular and metabolic basis of Clara cell tolerance to multiple doses of cytochrome P450-activated cytotoxicants. I: Bronchiolar epithelial reorganization and expression of cytochrome P450 monooxygenases in mice exposed to multiple doses of naphthalene.
      J Lakritz, A Chang, A Weir, S Nishio, D Hyde, R Philpot, A Buckpitt and C Plopper
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1408-1418;

  2. Lau, C E

    1. Tolerance to the anxiolytic effects of the triazolobenzodiazepines triazolam and alprazolam, as measured by the ingestion of a hypertonic sodium chloride solution in rats.
      E J Barbarito, C E Lau and J L Falk
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1201-1208;

  3. Lejarreta, M

    1. Specific serological response by active immunization with GD3-bearing liposomes.
      O Massó, S F Aliño, M Lejarreta, F Blasco and J Piulats
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1114-1120;

  4. Lemasters, J J

    1. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury.
      L C Trost and J J Lemasters
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1000-1005;

  5. Lemoine, H

    1. Is inhibition of oxygen radical production of neutrophils by sympathomimetics mediated via beta-2 adrenoceptors?
      M Weiss, E M Schneider, J Tarnow, S Mettler, M Krone, A Teschemacher and H Lemoine
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1105-1113;

  6. Lewis, T A

    1. Gallium arsenide selectively suppresses antigen processing by splenic macrophages for CD4+ T cell activation.
      T A Lewis, A E Munson and K L McCoy
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1244-1251;

  7. Loennechen, T

    1. Apoptosis and transmethylation metabolites in HL-60 cells.
      P C Endresen, T Loennechen, H Kildalsen and J Aarbakke
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1318-1324;

  8. Lonchampt, M

    1. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
      L Foissier, M Lonchampt, F Cogé and E Canet
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1484-1490;

  9. Lowe, J A

    1. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
      M D Aceto, S M Scates, J A Lowe and B R Martin
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1290-1295;

  10. Ludwig, J

    1. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
      J P Desjardins, B S Sproat, B Beijer, M Blaschke, M Dunkel, W Gerdes, J Ludwig, V Reither, T Rupp and P L Iversen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1419-1427;

M

  1. Maelicke, A

    1. Paraoxon: cholinesterase-independent stimulation of transmitter release and selective block of ligand-gated ion channels in cultured hippocampal neurons.
      E S Rocha, K L Swanson, Y Aracava, J E Goolsby, A Maelicke and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1175-1187;
    2. Diversity of nicotinic acetylcholine receptors in rat brain. V. alpha-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release.
      M Alkondon, E S Rocha, A Maelicke and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1460-1471;

  2. Malatynska, E

    1. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80.
      E Malatynska, Y Wang, R J Knapp, S Waite, S Calderon, K Rice, V J Hruby, H I Yamamura and W R Roeske
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1083-1089;

  3. Mansour, A

    1. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
      P J Emmerson, M J Clark, A Mansour, H Akil, J H Woods and F Medzihradsky
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1121-1127;

  4. Marek, G J

    1. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
      G J Marek and G K Aghajanian
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1373-1382;

  5. Martin, B R

    1. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
      M D Aceto, S M Scates, J A Lowe and B R Martin
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1290-1295;
    2. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
      V M Showalter, D R Compton, B R Martin and M E Abood
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 989-999;

  6. Martinez, R P

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

  7. Maryanoff, C A

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

  8. Massó, O

    1. Specific serological response by active immunization with GD3-bearing liposomes.
      O Massó, S F Aliño, M Lejarreta, F Blasco and J Piulats
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1114-1120;

  9. May, C

    1. Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity.
      C May, R I James, R Gunther and R S McIvor
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1444-1451;

  10. Mayumi, T

    1. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
      Y Tsutsumi, T Kihira, S Tsunoda, H Kamada, S Nakagawa, Y Kaneda, T Kanamori and T Mayumi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1006-1011;

  11. McCallum, G P

    1. Microsomal cytochrome P450 peroxygenase metabolism of arachidonic acid in guinea pig liver.
      G P McCallum, A C Weedon, P Krug and J R Bend
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1188-1194;

  12. McCoy, K L

    1. Gallium arsenide selectively suppresses antigen processing by splenic macrophages for CD4+ T cell activation.
      T A Lewis, A E Munson and K L McCoy
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1244-1251;

  13. McIntosh, J M

    1. Alpha-conotoxin-ImI: a competitive antagonist at alpha-bungarotoxin-sensitive neuronal nicotinic receptors in hippocampal neurons.
      E F Pereira, M Alkondon, J M McIntosh and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1472-1483;

  14. McIvor, R S

    1. Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity.
      C May, R I James, R Gunther and R S McIvor
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1444-1451;

  15. Mckown, L A

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

  16. Medzihradsky, F

    1. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
      P J Emmerson, M J Clark, A Mansour, H Akil, J H Woods and F Medzihradsky
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1121-1127;

  17. Meiri, K F

    1. Increased in vivo phosphorylation state of neuromodulin and synapsin I in striatum from rats treated with repeated amphetamine.
      S Iwata, G H Hewlett, S T Ferrell, A J Czernik, K F Meiri and M E Gnegy
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1428-1434;

  18. Mello, N K

    1. Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys.
      M B Gatch, S S Negus, N K Mello, S Archer and J M Bidlack
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1282-1289;

  19. Mettler, S

    1. Is inhibition of oxygen radical production of neutrophils by sympathomimetics mediated via beta-2 adrenoceptors?
      M Weiss, E M Schneider, J Tarnow, S Mettler, M Krone, A Teschemacher and H Lemoine
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1105-1113;

  20. Miller, H A

    1. Expression and modulation of 5-hydroxytryptamine1A receptors in P11 cells.
      J G Hensler, L S Cervera, H A Miller and J Corbitt
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1138-1145;

  21. Miller, S T

    1. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
      N A Sharif, S X Xu, S T Miller, D A Gamache and J M Yanni
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1252-1261;

  22. Minami, T

    1. Prostaglandin D2 inhibits prostaglandin E2-induced allodynia in conscious mice.
      T Minami, E Okuda-Ashitaka, H Mori, S Ito and O Hayaishi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1146-1152;

  23. Mizushima, Y

    1. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15.
      D Nakai, T Seita, T Terasaki, S Iwasa, Y Shoji, Y Mizushima and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1362-1372;

  24. Molta, C

    1. Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261.
      S Dionisotti, S Ferrara, C Molta, C Zocchi and E Ongini
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1209-1214;

  25. Mori, H

    1. Prostaglandin D2 inhibits prostaglandin E2-induced allodynia in conscious mice.
      T Minami, E Okuda-Ashitaka, H Mori, S Ito and O Hayaishi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1146-1152;

  26. Munson, A E

    1. Gallium arsenide selectively suppresses antigen processing by splenic macrophages for CD4+ T cell activation.
      T A Lewis, A E Munson and K L McCoy
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1244-1251;

N

  1. Nakagawa, S

    1. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
      Y Tsutsumi, T Kihira, S Tsunoda, H Kamada, S Nakagawa, Y Kaneda, T Kanamori and T Mayumi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1006-1011;

  2. Nakai, D

    1. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15.
      D Nakai, T Seita, T Terasaki, S Iwasa, Y Shoji, Y Mizushima and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1362-1372;

  3. Nakamura, H

    1. ONO-1078 antagonizes diarrhea-causing changes in ion transport and smooth muscle contraction induced by peptidoleukotrienes in rat and human colon in vitro.
      M Tominaga, H Tsukada, M Hosokawa, H Nakamura, T Taniguchi, S Ueda, M Sakai and M Okuma
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1058-1063;

  4. Negus, B H

    1. Effects of cocaine on anterior pituitary and gonadal hormones.
      C M Heesch, B H Negus, J E Bost, J H Keffer, R W Snyder and E J Eichhorn
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1195-1200;

  5. Negus, S S

    1. Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys.
      M B Gatch, S S Negus, N K Mello, S Archer and J M Bidlack
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1282-1289;

  6. Nemeroff, C B

    1. Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat.
      M J Owens, C A Ballenger, D L Knight and C B Nemeroff
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1040-1049;

  7. Niemann, C U

    1. Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly.
      T C Krejcie, T K Henthorn, C U Niemann, C Klein, D K Gupta, W B Gentry, C A Shanks and M J Avram
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1050-1057;

  8. Nishio, S

    1. Cellular and metabolic basis of Clara cell tolerance to multiple doses of cytochrome P450-activated cytotoxicants. I: Bronchiolar epithelial reorganization and expression of cytochrome P450 monooxygenases in mice exposed to multiple doses of naphthalene.
      J Lakritz, A Chang, A Weir, S Nishio, D Hyde, R Philpot, A Buckpitt and C Plopper
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1408-1418;

O

  1. Obar, R

    1. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor.
      P M Friden, T S Olson, R Obar, L R Walus and S D Putney
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1491-1498;

  2. Okuda-Ashitaka, E

    1. Prostaglandin D2 inhibits prostaglandin E2-induced allodynia in conscious mice.
      T Minami, E Okuda-Ashitaka, H Mori, S Ito and O Hayaishi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1146-1152;

  3. Okuma, M

    1. ONO-1078 antagonizes diarrhea-causing changes in ion transport and smooth muscle contraction induced by peptidoleukotrienes in rat and human colon in vitro.
      M Tominaga, H Tsukada, M Hosokawa, H Nakamura, T Taniguchi, S Ueda, M Sakai and M Okuma
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1058-1063;

  4. Olson, T S

    1. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor.
      P M Friden, T S Olson, R Obar, L R Walus and S D Putney
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1491-1498;

  5. Ongini, E

    1. Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261.
      S Dionisotti, S Ferrara, C Molta, C Zocchi and E Ongini
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1209-1214;

  6. Owens, M J

    1. Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat.
      M J Owens, C A Ballenger, D L Knight and C B Nemeroff
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1040-1049;

P

  1. Park, B K

    1. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene.
      N R Kitteringham, C Davis, N Howard, M Pirmohamed and B K Park
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1018-1027;

  2. Pazoles, C J

    1. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4.
      C R Turner, V L Cohan, J B Cheng, H J Showell, C J Pazoles and J W Watson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1349-1355;
    2. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
      V L Cohan, H J Showell, D A Fisher, C J Pazoles, J W Watson, C R Turner and J B Cheng
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1356-1361;

  3. Pereira, E F

    1. Alpha-conotoxin-ImI: a competitive antagonist at alpha-bungarotoxin-sensitive neuronal nicotinic receptors in hippocampal neurons.
      E F Pereira, M Alkondon, J M McIntosh and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1472-1483;

  4. Perkins, W J

    1. Use of nitric oxide-nucleophile adducts as biological sources of nitric oxide: effects on airway smooth muscle.
      A Hirasaki, K A Jones, W J Perkins and D O Warner
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1269-1275;

  5. Philpot, R

    1. Cellular and metabolic basis of Clara cell tolerance to multiple doses of cytochrome P450-activated cytotoxicants. I: Bronchiolar epithelial reorganization and expression of cytochrome P450 monooxygenases in mice exposed to multiple doses of naphthalene.
      J Lakritz, A Chang, A Weir, S Nishio, D Hyde, R Philpot, A Buckpitt and C Plopper
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1408-1418;

  6. Pirmohamed, M

    1. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene.
      N R Kitteringham, C Davis, N Howard, M Pirmohamed and B K Park
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1018-1027;

  7. Piulats, J

    1. Specific serological response by active immunization with GD3-bearing liposomes.
      O Massó, S F Aliño, M Lejarreta, F Blasco and J Piulats
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1114-1120;

  8. Plopper, C

    1. Cellular and metabolic basis of Clara cell tolerance to multiple doses of cytochrome P450-activated cytotoxicants. I: Bronchiolar epithelial reorganization and expression of cytochrome P450 monooxygenases in mice exposed to multiple doses of naphthalene.
      J Lakritz, A Chang, A Weir, S Nishio, D Hyde, R Philpot, A Buckpitt and C Plopper
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1408-1418;

  9. Pruett, S B

    1. Suppression of splenic natural killer cell activity in a mouse model for binge drinking. I. Direct effects of ethanol and its major metabolites are not primarily responsible for decreased natural killer cell activity.
      W J Wu and S B Pruett
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1325-1330;
    2. Suppression of splenic natural killer cell activity in a mouse model for binge drinking. II. Role of the neuroendocrine system.
      W J Wu and S B Pruett
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1331-1339;

  10. Putney, S D

    1. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor.
      P M Friden, T S Olson, R Obar, L R Walus and S D Putney
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1491-1498;

R

  1. Raffa, R B

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

  2. Reith, M E

    1. Modeling of the pH dependence of the binding of WIN 35,428 to the dopamine transporter in rat striatal membranes: is the bioactive form positively charged or neutral?
      C Xu and M E Reith
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1340-1348;

  3. Reither, V

    1. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
      J P Desjardins, B S Sproat, B Beijer, M Blaschke, M Dunkel, W Gerdes, J Ludwig, V Reither, T Rupp and P L Iversen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1419-1427;

  4. Rice, K

    1. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80.
      E Malatynska, Y Wang, R J Knapp, S Waite, S Calderon, K Rice, V J Hruby, H I Yamamura and W R Roeske
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1083-1089;

  5. Rocha, E S

    1. Paraoxon: cholinesterase-independent stimulation of transmitter release and selective block of ligand-gated ion channels in cultured hippocampal neurons.
      E S Rocha, K L Swanson, Y Aracava, J E Goolsby, A Maelicke and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1175-1187;
    2. Diversity of nicotinic acetylcholine receptors in rat brain. V. alpha-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release.
      M Alkondon, E S Rocha, A Maelicke and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1460-1471;

  6. Roerig, S C

    1. Spinal morphine/clonidine antinociceptive synergism: involvement of G proteins and N-type voltage-dependent calcium channels.
      Z Y Wei, F Karim and S C Roerig
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1392-1407;

  7. Roeske, W R

    1. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80.
      E Malatynska, Y Wang, R J Knapp, S Waite, S Calderon, K Rice, V J Hruby, H I Yamamura and W R Roeske
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1083-1089;

  8. Rupp, T

    1. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
      J P Desjardins, B S Sproat, B Beijer, M Blaschke, M Dunkel, W Gerdes, J Ludwig, V Reither, T Rupp and P L Iversen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1419-1427;

S

  1. Sakai, M

    1. ONO-1078 antagonizes diarrhea-causing changes in ion transport and smooth muscle contraction induced by peptidoleukotrienes in rat and human colon in vitro.
      M Tominaga, H Tsukada, M Hosokawa, H Nakamura, T Taniguchi, S Ueda, M Sakai and M Okuma
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1058-1063;

  2. Scates, S M

    1. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
      M D Aceto, S M Scates, J A Lowe and B R Martin
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1290-1295;

  3. Scheidegger, K J

    1. Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats.
      K J Scheidegger, J M Wood, H van Essen and H A Struijker-Boudier
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1276-1281;

  4. Schneider, E M

    1. Is inhibition of oxygen radical production of neutrophils by sympathomimetics mediated via beta-2 adrenoceptors?
      M Weiss, E M Schneider, J Tarnow, S Mettler, M Krone, A Teschemacher and H Lemoine
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1105-1113;

  5. Schnellmann, R G

    1. Extracellular acidosis and chloride channel inhibitors act in the late phase of cellular injury to prevent death.
      S L Waters and R G Schnellmann
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1012-1017;

  6. Schriefer, J A

    1. Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model.
      J A Schriefer, E P Broudy and A H Hassen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1034-1039;

  7. Schupsky, J J

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

  8. Seita, T

    1. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15.
      D Nakai, T Seita, T Terasaki, S Iwasa, Y Shoji, Y Mizushima and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1362-1372;

  9. Shanks, C A

    1. Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly.
      T C Krejcie, T K Henthorn, C U Niemann, C Klein, D K Gupta, W B Gentry, C A Shanks and M J Avram
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1050-1057;

  10. Sharif, N A

    1. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
      N A Sharif, S X Xu, S T Miller, D A Gamache and J M Yanni
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1252-1261;

  11. Sheller, J

    1. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
      Y Caraco, J Sheller and A J Wood
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1165-1174;

  12. Shen, Y T

    1. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs.
      Y T Shen, P Cervoni, T Claus and S F Vatner
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1435-1443;

  13. Shoji, Y

    1. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15.
      D Nakai, T Seita, T Terasaki, S Iwasa, Y Shoji, Y Mizushima and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1362-1372;

  14. Showalter, V M

    1. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
      V M Showalter, D R Compton, B R Martin and M E Abood
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 989-999;

  15. Showell, H J

    1. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4.
      C R Turner, V L Cohan, J B Cheng, H J Showell, C J Pazoles and J W Watson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1349-1355;
    2. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
      V L Cohan, H J Showell, D A Fisher, C J Pazoles, J W Watson, C R Turner and J B Cheng
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1356-1361;

  16. Singh, J P

    1. Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran.
      T R Wiernicki, J S Bean, C Dell, A Williams, D Wood, R F Kauffman and J P Singh
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1452-1459;

  17. Slesak, G

    1. Significance of endothelinB receptors for myocardial contractility and myocardial energy metabolism.
      M E Beyer, G Slesak and H M Hoffmeister
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1228-1234;

  18. Smith, M D

    1. Effects of benzodiazepine agonist exposure on corticotropin-releasing factor content and hormonal stress responses: divergent responses in male and ovariectomized female rats.
      M A Wilson, R Biscardi, M D Smith and S P Wilson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1073-1082;

  19. Snyder, R W

    1. Effects of cocaine on anterior pituitary and gonadal hormones.
      C M Heesch, B H Negus, J E Bost, J H Keffer, R W Snyder and E J Eichhorn
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1195-1200;

  20. Spealman, R D

    1. Dopamine D3 receptor agonists partially reproduce the discriminative stimulus effects of cocaine in squirrel monkeys.
      R D Spealman
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1128-1137;

  21. Sproat, B S

    1. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
      J P Desjardins, B S Sproat, B Beijer, M Blaschke, M Dunkel, W Gerdes, J Ludwig, V Reither, T Rupp and P L Iversen
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1419-1427;

  22. Struijker-Boudier, H A

    1. Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats.
      K J Scheidegger, J M Wood, H van Essen and H A Struijker-Boudier
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1276-1281;

  23. Sugiyama, Y

    1. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15.
      D Nakai, T Seita, T Terasaki, S Iwasa, Y Shoji, Y Mizushima and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1362-1372;

  24. Swanson, C J

    1. Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats.
      A E Kelley, E P Bless and C J Swanson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1499-1507;

  25. Swanson, K L

    1. Paraoxon: cholinesterase-independent stimulation of transmitter release and selective block of ligand-gated ion channels in cultured hippocampal neurons.
      E S Rocha, K L Swanson, Y Aracava, J E Goolsby, A Maelicke and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1175-1187;

T

  1. Takacs, A N

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

  2. Takahashi, K

    1. Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
      T Takahashi, K Takahashi, S Kishi-Tanikawa, K Tsuchida, H Araki and S Higuchi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1028-1033;

  3. Takahashi, T

    1. Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
      T Takahashi, K Takahashi, S Kishi-Tanikawa, K Tsuchida, H Araki and S Higuchi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1028-1033;

  4. Taniguchi, T

    1. ONO-1078 antagonizes diarrhea-causing changes in ion transport and smooth muscle contraction induced by peptidoleukotrienes in rat and human colon in vitro.
      M Tominaga, H Tsukada, M Hosokawa, H Nakamura, T Taniguchi, S Ueda, M Sakai and M Okuma
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1058-1063;

  5. Tarnow, J

    1. Is inhibition of oxygen radical production of neutrophils by sympathomimetics mediated via beta-2 adrenoceptors?
      M Weiss, E M Schneider, J Tarnow, S Mettler, M Krone, A Teschemacher and H Lemoine
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1105-1113;

  6. Terasaki, T

    1. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15.
      D Nakai, T Seita, T Terasaki, S Iwasa, Y Shoji, Y Mizushima and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1362-1372;

  7. Teschemacher, A

    1. Is inhibition of oxygen radical production of neutrophils by sympathomimetics mediated via beta-2 adrenoceptors?
      M Weiss, E M Schneider, J Tarnow, S Mettler, M Krone, A Teschemacher and H Lemoine
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1105-1113;

  8. Thomas, G P

    1. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion.
      G P Thomas, G R Ferrier and S E Howlett
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1090-1097;

  9. Tominaga, M

    1. ONO-1078 antagonizes diarrhea-causing changes in ion transport and smooth muscle contraction induced by peptidoleukotrienes in rat and human colon in vitro.
      M Tominaga, H Tsukada, M Hosokawa, H Nakamura, T Taniguchi, S Ueda, M Sakai and M Okuma
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1058-1063;

  10. Trost, L C

    1. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury.
      L C Trost and J J Lemasters
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1000-1005;

  11. Tsuchida, K

    1. Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
      T Takahashi, K Takahashi, S Kishi-Tanikawa, K Tsuchida, H Araki and S Higuchi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1028-1033;

  12. Tsukada, H

    1. ONO-1078 antagonizes diarrhea-causing changes in ion transport and smooth muscle contraction induced by peptidoleukotrienes in rat and human colon in vitro.
      M Tominaga, H Tsukada, M Hosokawa, H Nakamura, T Taniguchi, S Ueda, M Sakai and M Okuma
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1058-1063;

  13. Tsunoda, S

    1. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
      Y Tsutsumi, T Kihira, S Tsunoda, H Kamada, S Nakagawa, Y Kaneda, T Kanamori and T Mayumi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1006-1011;

  14. Tsutsumi, Y

    1. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
      Y Tsutsumi, T Kihira, S Tsunoda, H Kamada, S Nakagawa, Y Kaneda, T Kanamori and T Mayumi
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1006-1011;

  15. Turner, C R

    1. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4.
      C R Turner, V L Cohan, J B Cheng, H J Showell, C J Pazoles and J W Watson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1349-1355;
    2. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
      V L Cohan, H J Showell, D A Fisher, C J Pazoles, J W Watson, C R Turner and J B Cheng
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1356-1361;

U

  1. Ueda, S

    1. ONO-1078 antagonizes diarrhea-causing changes in ion transport and smooth muscle contraction induced by peptidoleukotrienes in rat and human colon in vitro.
      M Tominaga, H Tsukada, M Hosokawa, H Nakamura, T Taniguchi, S Ueda, M Sakai and M Okuma
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1058-1063;

V

  1. van Essen, H

    1. Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats.
      K J Scheidegger, J M Wood, H van Essen and H A Struijker-Boudier
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1276-1281;

  2. Vatner, S F

    1. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs.
      Y T Shen, P Cervoni, T Claus and S F Vatner
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1435-1443;

  3. Villani, F J

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

W

  1. Waite, S

    1. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80.
      E Malatynska, Y Wang, R J Knapp, S Waite, S Calderon, K Rice, V J Hruby, H I Yamamura and W R Roeske
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1083-1089;

  2. Wallace, T L

    1. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.
      T L Wallace, S A Bazemore, D J Kornbrust and P A Cossum
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1306-1312;
    2. Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys.
      T L Wallace, S A Bazemore, D J Kornbrust and P A Cossum
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1313-1317;

  3. Walus, L R

    1. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor.
      P M Friden, T S Olson, R Obar, L R Walus and S D Putney
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1491-1498;

  4. Wang, Y

    1. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80.
      E Malatynska, Y Wang, R J Knapp, S Waite, S Calderon, K Rice, V J Hruby, H I Yamamura and W R Roeske
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1083-1089;

  5. Warner, D O

    1. Use of nitric oxide-nucleophile adducts as biological sources of nitric oxide: effects on airway smooth muscle.
      A Hirasaki, K A Jones, W J Perkins and D O Warner
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1269-1275;

  6. Waters, S L

    1. Extracellular acidosis and chloride channel inhibitors act in the late phase of cellular injury to prevent death.
      S L Waters and R G Schnellmann
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1012-1017;

  7. Watson, J W

    1. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4.
      C R Turner, V L Cohan, J B Cheng, H J Showell, C J Pazoles and J W Watson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1349-1355;
    2. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
      V L Cohan, H J Showell, D A Fisher, C J Pazoles, J W Watson, C R Turner and J B Cheng
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1356-1361;

  8. Weedon, A C

    1. Microsomal cytochrome P450 peroxygenase metabolism of arachidonic acid in guinea pig liver.
      G P McCallum, A C Weedon, P Krug and J R Bend
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1188-1194;

  9. Wei, Z Y

    1. Spinal morphine/clonidine antinociceptive synergism: involvement of G proteins and N-type voltage-dependent calcium channels.
      Z Y Wei, F Karim and S C Roerig
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1392-1407;

  10. Weir, A

    1. Cellular and metabolic basis of Clara cell tolerance to multiple doses of cytochrome P450-activated cytotoxicants. I: Bronchiolar epithelial reorganization and expression of cytochrome P450 monooxygenases in mice exposed to multiple doses of naphthalene.
      J Lakritz, A Chang, A Weir, S Nishio, D Hyde, R Philpot, A Buckpitt and C Plopper
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1408-1418;

  11. Weiss, M

    1. Is inhibition of oxygen radical production of neutrophils by sympathomimetics mediated via beta-2 adrenoceptors?
      M Weiss, E M Schneider, J Tarnow, S Mettler, M Krone, A Teschemacher and H Lemoine
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1105-1113;

  12. Wiernicki, T R

    1. Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran.
      T R Wiernicki, J S Bean, C Dell, A Williams, D Wood, R F Kauffman and J P Singh
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1452-1459;

  13. Williams, A

    1. Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran.
      T R Wiernicki, J S Bean, C Dell, A Williams, D Wood, R F Kauffman and J P Singh
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1452-1459;

  14. Wilson, M A

    1. Effects of benzodiazepine agonist exposure on corticotropin-releasing factor content and hormonal stress responses: divergent responses in male and ovariectomized female rats.
      M A Wilson, R Biscardi, M D Smith and S P Wilson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1073-1082;

  15. Wilson, S P

    1. Effects of benzodiazepine agonist exposure on corticotropin-releasing factor content and hormonal stress responses: divergent responses in male and ovariectomized female rats.
      M A Wilson, R Biscardi, M D Smith and S P Wilson
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1073-1082;

  16. Wood, A J

    1. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
      Y Caraco, J Sheller and A J Wood
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1165-1174;

  17. Wood, D

    1. Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran.
      T R Wiernicki, J S Bean, C Dell, A Williams, D Wood, R F Kauffman and J P Singh
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1452-1459;

  18. Wood, J M

    1. Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats.
      K J Scheidegger, J M Wood, H van Essen and H A Struijker-Boudier
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1276-1281;

  19. Woods, J H

    1. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
      P J Emmerson, M J Clark, A Mansour, H Akil, J H Woods and F Medzihradsky
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1121-1127;

  20. Wu, W J

    1. Suppression of splenic natural killer cell activity in a mouse model for binge drinking. I. Direct effects of ethanol and its major metabolites are not primarily responsible for decreased natural killer cell activity.
      W J Wu and S B Pruett
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1325-1330;
    2. Suppression of splenic natural killer cell activity in a mouse model for binge drinking. II. Role of the neuroendocrine system.
      W J Wu and S B Pruett
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1331-1339;

  21. Wu, W N

    1. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride.
      R B Raffa, M L Haslego, C A Maryanoff, F J Villani, E E Codd, C D Connelly, R P Martinez, J J Schupsky, J A Buben, W N Wu, A N Takacs and L A Mckown
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1098-1104;

X

  1. Xu, C

    1. Modeling of the pH dependence of the binding of WIN 35,428 to the dopamine transporter in rat striatal membranes: is the bioactive form positively charged or neutral?
      C Xu and M E Reith
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1340-1348;

  2. Xu, S X

    1. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
      N A Sharif, S X Xu, S T Miller, D A Gamache and J M Yanni
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1252-1261;

Y

  1. Yamamura, H I

    1. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80.
      E Malatynska, Y Wang, R J Knapp, S Waite, S Calderon, K Rice, V J Hruby, H I Yamamura and W R Roeske
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1083-1089;

  2. Yanni, J M

    1. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
      N A Sharif, S X Xu, S T Miller, D A Gamache and J M Yanni
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1252-1261;

Z

  1. Zocchi, C

    1. Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261.
      S Dionisotti, S Ferrara, C Molta, C Zocchi and E Ongini
      Journal of Pharmacology and Experimental Therapeutics September 1996, 278 (3) 1209-1214;
Back to top

In this issue

Advertisement